In addition, a clinical cohort study in intermediate and high cytogenetic risk AML showed that patients with a high percentage of ALDH + had adverse outcomes.24, 26, 27 However, this effect has not been evaluated in t(8;21) AML patients to date. This evidence concerns the gene LDHA and acute myeloid leukemia.